

Synthesis and Biological Evaluation of Hydroxamate-Based Iron Chelators


Raymond J. Bergeron,* Jan Wiegand, James S. McManis, and P. Thirumalai Perumal

Department of Medicinal Chemistry, J. Hillis Miller Health Center, University of Florida, Gainesville, Florida 32610.
Received February 20, 1991

A new and versatile route to desferrioxamine B (DFO, 1) is described. Hydroxamate reagent 4 was elaborated in a series of high yield steps to the *tert*-butoxycarbonyl nitrile 11, which provided DFO in three transformations. The intermediate 11 could also be utilized in the preparation of DFO analogues which contain terminal *N*-acyl groups other than acetyl. The methodology was further employed in the syntheses of the DFO polyether analogues 2 and 3, beginning with the 3,6,9-trioxadecylation of *N*-(*tert*-butoxycarbonyl)-*O*-benzylhydroxylamine. Polyethers 2 and 3 are neutral molecules, which are somewhat more lipophilic than the parent DFO. Polyether hydroxamate 2 was shown to be nearly 3 times as effective as desferrioxamine at clearing iron in rats.

Microorganisms produce a group of low molecular weight chelators, siderophores,¹⁻⁶ for the purpose of acquiring iron. The metal exists in the biosphere largely in the insoluble ferric state and would be otherwise inaccessible to bacteria without such ligands. Although a large number of siderophores have been identified, they fall largely into two structural classes: the catecholamides and the hydroxamates.¹ Many of the ligands of both structural types contain polyamine backbones. While the hexacoordinate catecholamides parabactin² and vibriobactin³ are predicated on the substituted triamines spermidine and norspermidine, respectively, the hydroxamates are frequently derived from the diamines putrescine or cadaverine, or from their biochemical precursors, ornithine or lysine.¹ For example, the siderophores isolated from *Streptomyces pilosus*, desferrioxamines A-I, consist of a group of hydroxamates with either repeating putrescine or cadaverine units in their backbones.⁴ The most well-known of these chelators, desferrioxamine B (DFO),⁵ is a linear trihydroxamate ligand, which forms a very stable hexacoordinate, octahedral complex⁶ with iron(III), $K_f = 1 \times 10^{30} \text{ M}^{-1}$. Although DFO binds a number of different 3+ cations, e.g. Al(III), Ga(III), Cr(III), it exhibits a high specificity for iron(III). It is not too surprising then that the mesylate salt of desferrioxamine, Desferal, has been employed in the treatment of several iron-overload diseases such as thalassemia.^{7,8} However, the fact that patients must be continuously infused because of the drug's short half-life in the body has compelled investigators to continue the search for better therapeutic iron chelators.

Scheme I. A New and Versatile Synthesis of Desferrioxamine B (DFO, 1)



- Bergeron, R. J. Synthesis and solution structures of microbial siderophores. *Chem. Rev.* 1984, 84, 587-602.
- Tait, G. H. The Identification and Biosynthesis of Siderochromes Formed by *Micrococcus denitrificans*. *Biochem. J.* 1975, 146, 191-204.
- Griffiths, G. L.; Sigel, S. P.; Payne, S. M.; Neilands, J. B. Vibriobactin, a Siderophore from *Vibrio cholerae*. *J. Biol. Chem.* 1984, 259, 383-385.
- Aksoy, M.; Birdwood, G. F. B. *Hypertransfusion and Iron Chelation in Thalassemia*; Hans Huber Publishers: Berne, 1985; p 80.
- Bickel, H.; Hall, G. E.; Keller-Schierlein, W.; Prelog, V.; Vischer, E.; Wettstein, A. Metabolic products of actinomycetes. Ferrioxamine B. *Helv. Chim. Acta* 1960, 43, 2129-2138.
- Modell, B.; Berdoukas, V. *The Clinical Approach to Thalassemia*; Grune and Stratton: London, 1984; p 217.
- Anderson, W. F. *Inorganic Chemistry in Biology and Medicine*; American Chemical Society: Washington, DC, 1973; Chapter 15.
- Fisher, E. A.; McLachlan, D. R.; Kruck, T. P. A.; Mustard, R. A. Development of an Intravenous Desferrioxamine Mesylate Treatment Protocol for Swine: Monitoring of Desferrioxamine and Metabolites by High-Performance Liquid Chromatography. *Pharmacology* 1990, 41, 263-271.

Results and Discussion

Synthesis. We report a new and versatile route to DFO (1) (Figure 1), predicated on our triprotected *N*-hydroxycadaverine reagent.⁹ We have published a total synthesis

- Bergeron, R. J.; McManis, J. S. The total synthesis of bisucaberin. *Tetrahedron* 1989, 45, 4939-4944.




Figure 1. Desferrioxamine B (DFO, 1), acetyl triether 2, and bis(triether) 3.

of DFO,¹⁰ in which the construction moved from the *N*-acetyl to the primary amine end of the molecule. The new scheme proceeds in the opposite direction, avoids some of the problems associated with reduction steps, is of high overall yield, and begins with easily accessible starting materials. The methodology was utilized to access several desferrioxamine analogues that showed promising activity in terms of their ability to remove iron from rats. These derivatives include polyether-containing ligands 2 and 3 (Figure 1), which were designed to be lipophilic. In both instances this change in solubility properties rendered the drug more effective than desferrioxamine at removing iron in our rodent model.

The new route (Scheme I) began with the generation and selective deprotection of triprotected *N*-hydroxycadaverine 4, also used to prepare bisucaberin.⁹ The backbone of DFO was constructed by a series of acylations such that the acetyl function was attached at the end of the synthesis. In the key synthon 4, the primary amine was masked as a nitrile, while the hydroxylamine was *N*-(*tert*-butoxycarbonyl)-*O*-benzyl diprotected. The synthesis of reagent 4 began with the conversion of *O*-benzylhydroxylamine hydrochloride to its *N*-(*tert*-butoxycarbonyl) derivative,¹¹ which is crystalline, stable, and available in a single step from commercial reagents. *N*-(*tert*-butoxycarbonyl)-*O*-benzylhydroxylamine was *N*-alkylated with 5-chlorovaleronitrile (NaH, DMF, NaI) to give *O*-benzyl-*N*-(*tert*-butoxycarbonyl)-*N*-(4-cyanobutyl)hydroxylamine 4. The *O*-benzyl protecting group in 4 was left intact until hydrogenation (Pd-C) to the final product 1. *N*-(*tert*-butoxycarbonyl)-*O*-benzylhydroxylamine can also be *N*-alkylated with commercially available ω -chloroalkanenitriles to either shorten or lengthen the *N*-hydroxydiamine chain. Thus, the length of DFO can be varied through this flexible synthetic strategy. In contrast, the previous synthesis¹⁰ of DFO began with 4-cyanobutanal, which was made by a tedious method and is somewhat unstable. Moreover, if one wanted to vary the length of the *N*-hydroxydiamine chains of DFO, a new and reactive cyano aldehyde would be required.

Brief exposure of *N*-(*tert*-butoxycarbonyl) nitrile 4 to trifluoroacetic acid (TFA) resulted in collapse to carbon dioxide, isobutylene, and *O*-benzyl-*N*-(4-cyanobutyl)-

hydroxylamine (5), thus freeing up the hydroxylamine nitrogen. Alternatively, the nitrile in 4 was selectively hydrogenated with W-2 grade Raney nickel in methanolic ammonia in the presence of the benzyl group to generate primary amine 7. This high-yield reaction required no prewashing of the catalyst. In the previous route,¹⁰ even with such pretreatment of the nickel catalyst, hydrogenation of nitriles which contained the base-sensitive succinate unit occurred in variable yields. Benzyloxyamine 5 was acylated with succinic anhydride in hot pyridine to give half-acid nitrile 6.¹⁰ If succinic anhydride were replaced with glutaric anhydride in Scheme I, homologues of DFO could easily be generated. Coupling of acid 6 with primary amine 7 was carried out with diphenyl phosphorazidate, the Yamada reagent,¹² (NEt₃/DMF) to afford masked tetracoordinate ligand 8. The phosphoryl azide proved to be a superior amide coupling agent to dicyclohexylcarbodiimide (DCC), which had been employed in the previous synthesis.¹⁰ The yields were consistently higher and the phosphorus-containing byproduct could be washed away from the product, in contrast to dicyclohexylurea (DCU). The elaboration was repeated: *tert*-butoxycarbonyl nitrile 8 was treated with TFA to give benzyloxyamine 9. Acylation of 9 with succinic anhydride as before generated nitrile acid 10, which was in turn reacted with diprotected cadaverine 7 and the Yamada reagent to give *tert*-butoxycarbonyl nitrile 11, a versatile precursor to hexacoordinate chelators. In addition to providing DFO (1) in three transformations, nitrile 11 permitted us to chemically modify DFO at both the acyl and the amino termini for the purpose of determining the structure-activity relationship. The terminal *tert*-butoxycarbonyl-protecting group of 11 can be replaced with any acyl functionality that one chooses. In the previous method¹⁰ the acetyl group was attached early in the sequence, thus restricting the versatility of that synthesis. Alternatively the cyano group in 11 could be selectively hydrogenated with prewashed Raney nickel in methanolic ammonia, and then the amino end of DFO could be modified by using an active ester or other electrophile. In order to complete the synthesis of DFO (1), acid-promoted deprotection of 11 to benzyloxyamine 12 was followed by acylation with acetic anhydride in pyridine to give masked DFO 13. Simultaneous catalytic reduction of the nitrile and removal of the *O*-benzyl protecting groups as before¹⁰ generated the natural product DFO (1).

The short half-life of DFO in the body and the fact that patients must be continuously infused led investigators to prepare and test analogues of DFO as potential therapeutic iron chelators. In the search for useful analogues of DFO, we previously determined that replacement of the terminal 5-aminopentyl unit of desferrioxamine B with a heptyl group rendered the molecule very insoluble in a variety of different vehicles.¹⁰ Therefore, polyether analogues of DFO, chelators 2 and 3 in Figure 1, were prepared in order to enhance the chelator's lipophilicity as well as to maintain some degree of aqueous solubility. Specifically, in DFO polyether analogue 2, the charged 5-aminopentyl chain was replaced with a neutral triether chain, and in

(10) Bergeron, R. J.; Pegram, J. J. An efficient total synthesis of desferrioxamine B. *J. Org. Chem.* 1988, 53, 3131-3134.

(11) Ramasamy, K.; Olsen, R. K.; Emery, T. *N*-Methylation of *O*-Benzyl *N*-(Alkoxy-carbonyl)- α -Amino Acid Hydroxamate Derivatives. *J. Org. Chem.* 1981, 46, 5438-5441.

(12) Shioiri, T.; Ninomiya, K.; Yamada, S. Diphenylphosphoryl Azide. A New Convenient Reagent for a Modified Curtius Reaction and for the Peptide Synthesis. *J. Am. Chem. Soc.* 1972, 94, 6203-6205.

(13) Schultz, R. A.; White, B. D.; Dishong, D. M.; Arnold, K. A.; Gokel, G. W. 12-, 15-, and 18-Membered-Ring Nitrogen-Pivot Lariat Ethers: Syntheses, Properties, and Sodium and Ammonium Cation Binding Properties. *J. Am. Chem. Soc.* 1985, 107, 6659-6668.

Table I. A Comparison of the Total Iron Output Induced by DFO (po) and Analogues 2 and 3 (po), over 24 h, per Kilogram of Rat Weight

time, h	control	DFO	2	3
Bile				
3	9.1 (±1.2)	14.7 (±5.2)	20.2 (±3.5)	16.3 (±6.5)
6	17.4 (±2.3)	43.9 (±13.7)	42.8 (±7.7)	31.7 (±7.8)
9	24.7 (±2.3)	76.8 (±19.6)	56.8 (±8.1)	42.5 (±8.0)
12	31.6 (±2.9)	97.1 (±21.9)	67.5 (±8.5)	59.7 (±14.6)
15	37.1 (±3.0)	110.8 (±22.9)	76.5 (±8.6)	67.9 (±14.8)
18	42.4 (±3.0)	119.8 (±22.9)	83.8 (±8.8)	74.6 (±14.9)
21	47.9 (±3.4)	128.7 (±23.0)	89.0 (±8.8)	81.3 (±15.2)
24	53.5 (±3.6)	135.0 (±23.1)	93.7 (±8.8)	86.6 (±15.4)
Urine				
24	11.7 (±1.3)	16.5 (±1.0)	15.0 (±3.2)	13.3 (±6.6)
Total				
	65.2 (±3.8)	151.5 (±23.1)	108.7 (±9.4)	99.8 (±16.7)
Induced Iron (Treated-Control)				
	-	86.3	43.5	34.6


bis(polyether) 3, the acetyl of DFO was substituted, as well, by a triether acyl group. The syntheses of chelators 2 and 3 utilized the new DFO synthetic methodology (Scheme I) and are illustrated in Scheme II.

The monomethyl ether of triethylene glycol was converted to its tosylate,¹³ which was used to alkylate *N*-(*tert*-butoxycarbonyl)-*O*-benzylhydroxylamine (NaH/DMF), resulting in polyether 14. By contrast, the methodology of the old route¹⁰ required conversion of the alcohol to the corresponding reactive aldehyde instead of the tosylate. The alkylated product 14 was elaborated in the manner of the DFO synthesis (Scheme I): stirring it with TFA in CH₂Cl₂ gave 15, which was then acylated with succinic anhydride to afford carboxylic acid 16. Coupling of 16 and primary amine 7 was carried out in high yield with the phosphorazidate reagent to tetracoordinate equivalent 17. The protected hexacoordinate reagent 20 was obtained in high overall yield from 17 by repeating the same three conversions. Acid cleavage of the *tert*-butoxycarbonyl group in 20 furnished benzyloxylamine 21, which can be reacted with a wide range of activated esters to give any hexacoordinate polyether chelator that we choose, after catalytic debenzoylation. Amine 21 was acylated with acetic anhydride (pyr/room temperature) to produce 22 or with 3,6,9-trioxadecanoyl chloride¹⁴ (NEt₃/CH₂Cl₂) to afford 23. Catalytic debenzoylation of 22 and 23 gave hexacoordinate ligands 2 and 3, respectively. Both of these chelators are soluble in water and chloroform and thus possess enhanced lipophilicity and the aqueous solubility of DFO.

Biological Results. Acetyl triether 2 and bis(triether) 3 were evaluated in a non-iron-overloaded bile duct cannulated rat model.^{15,16} Studies involved both subcutaneous and oral administration of the drugs in Cremophor RH-40/water (40/60 v/v). The chelator-promoted iron excretion was monitored in both the bile and the urine, and the results were compared to those for a standard desferrioxamine dose given either orally (po) or subcutaneously (sc) also given in Cremophor RH-40/water. The

Table II. A Comparison of the Total Iron Output Induced by DFO (sc) and Analogues 2 and 3 (sc), over 24 h, per Kilogram of Rat Weight

time, h	control	DFO	2	3
Bile				
3	9.1 (±1.2)	43.6 (±18.2)	117.3 (±26.7)	106.9 (±6.8)
6	17.4 (±2.3)	105.9 (±21.2)	262.5 (±27.9)	244.4 (±11.4)
9	24.7 (±2.3)	152.8 (±22.3)	374.6 (±28.7)	362.6 (±21.1)
12	31.6 (±2.9)	173.9 (±22.9)	456.1 (±32.3)	467.7 (±33.7)
15	37.1 (±3.0)	196.2 (±25.9)	519.6 (±39.2)	509.1 (±38.5)
18	42.4 (±3.0)	210.7 (±27.8)	561.2 (±42.4)	526.2 (±39.2)
21	47.9 (±3.4)	219.8 (±27.8)	585.9 (±43.4)	534.2 (±39.3)
24	53.5 (±3.6)	228.4 (±27.9)	599.5 (±43.7)	539.7 (±39.3)
Urine				
24	11.7 (±1.3)	49.2 (±19.8)	68.4 (±17.5)	45.3 (±4.8)
Total				
	65.2 (±3.8)	277.6 (±34.2)	667.9 (±47.0)	585.0 (±39.6)
Induced Iron (Treated-Control)				
	-	212.4	602.7	519.8

**Figure 2.** A comparison of the cumulative biliary iron clearance induced by analogues 2 and 3 with that of DFO when all are administered orally.

rats were fasted for 48 h prior to drug administration and throughout the course of the experiment. The iron excretion data for the drugs evaluated in this study are reported in Tables I and II with comparative data for po and sc desferrioxamine. The data are presented in total "induced" iron excreted over 24 h, per kilogram of rat weight. The values are derived from the difference between the total iron excreted in test animals vs control animals on a per weight basis. This measurement does not speak to potential enterohepatic absorption, where the iron-chelator complex may be reabsorbed and thus decrease the amount of iron cleared, but only to the ability of the drug to access iron stores.

Polyether DFO analogue 2, when administered orally at 150 µmol/kg to fasted rats, was 0.50 times as effective as DFO administered orally at the same dose. Bis(triether) analogue 3, also given orally to fasted rats, was 0.40 times as effective as DFO (po) and 0.80 times as effective as chelator 2 (Figure 2). Urinary iron clearance was unremarkable in all of the animals, with iron excretion only slightly higher than that observed in the control (Cremophor/water) animals.

When either ligand 2 or 3 was administered subcutaneously at 150 µmol/kg, far more iron was excreted than with DFO administered subcutaneously at the same dose (in µmol/kg). Analogue 2 was nearly three times as effective as DFO in promoting iron clearance, while 3 was 2.5 times as effective as DFO (Figure 3).

(14) Heimann, U.; Voegtli, F. Hydrophilic lipids. *Liebigs Ann. Chem.* 1980, 858-862.

(15) Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Vinson, J. R. T.; Luchetta, G.; Evans, K. M.; Peter, H.; Jenny, H.-B. A comparative evaluation of iron clearance models. *Ann. N. Y. Acad. Sci.* 1990, 612, 378-393.

(16) Bergeron, R. J.; Wiegand, J.; Dionis, J. B.; Egli-Karmakka, M.; Frei, J.; Huxley-Tencer, A.; Peter, H. H. Evaluation of desferrioxamine and its synthetic analogues as orally effective iron chelators. *J. Med. Chem.* 1991, 34, 2072-2078.

above the metabolic cage. This system allowed the animal to move freely in the cage while continuous bile samples were being collected. Bile samples were collected at 3-h intervals. Urine samples were taken every 24 h.

N-(*tert*-Butoxycarbonyl)-*N*-(4-cyanobutyl)-*O*-benzylhydroxylamine (4) was synthesized in these laboratories⁹ in quantitative yield.

N-(4-Cyanobutyl)-*O*-benzylhydroxylamine (5) was synthesized in these laboratories⁹ in 81% yield.

N-(Benzoyloxy)-*N*-(4-cyanobutyl)succinamic acid (6) was prepared by our method in 98% yield.^{9,10}

N-(5-Aminopentyl)-*N*-(*tert*-butoxycarbonyl)-*O*-benzylhydroxylamine (7) was made in 92% yield according to our published procedure.⁹

17-(*tert*-Butoxycarbonyl)-6,17-bis(benzoyloxy)-7,10-dioxo-6,11,17-triazaheptadecanenitrile (8). Acid 6 (3.1 g, 10.2 mmol) and amine 7 (3.4 g, 11.0 mmol) were dissolved in distilled DMF (50 mL), and the solution was cooled to 0 °C under N₂. Diphenyl phosphorazidate (3.1 g, 11.3 mmol) and triethylamine (2.2 g, 22 mmol) were added, and the solution was stirred in the cold bath for 5 h and at room temperature for 12 h. Solvent was removed in vacuo, followed by a CHCl₃ workup and column chromatography on silica gel, eluting with 5% CH₃OH/CHCl₃, to give 6.00 g (99%) of 8.⁹

6,17-Bis(benzoyloxy)-7,10-dioxo-6,11,17-triazaheptadecanenitrile (9). Trifluoroacetic acid (TFA, 40 mL) was added slowly to 8 (6.00 g, 10.1 mmol) in CH₂Cl₂ (100 mL). The solution was stirred at 0 °C for 15 min and at room temperature for 30 min. Solvents were removed by rotary evaporation, aqueous NaHCO₃ was added, and the product was extracted into CHCl₃. Column chromatography on silica gel, eluting with 5% CH₃OH/CHCl₃, afforded 4.3 g (87%) of 9.⁹

5,16-Bis(benzoyloxy)-20-cyano-4,12,15-trioxo-5,11,16-triazaeicosanoic acid (10) was synthesized in these laboratories in 96% yield.⁹

28-(*tert*-Butoxycarbonyl)-6,17,28-tris(benzoyloxy)-7,10,18,21-tetraoxo-6,11,17,22,28-pentaazaocacosanenitrile (11). Acid 10 (3.8 g, 6.4 mmol) and amine 7 (2.2 g, 7.1 mmol) were coupled by using diphenyl phosphorazidate and the method of 8 to give, after column chromatography (5% CH₃OH/CHCl₃), 5.4 g (95%) of 11.¹⁷

6,17,28-Tris(benzoyloxy)-7,10,18,21-tetraoxo-6,11,17,22,28-pentaazaocacosanenitrile (12) was prepared by our procedure in quantitative yield.¹⁷

6,17,28-Tris(benzoyloxy)-7,10,18,21,29-pentaoxo-6,11,17,22,28-pentaazatriacontanenitrile (13). Compound 12 (1.1 g, 1.4 mmol) was dissolved in pyridine (16 mL), acetic anhydride (4 mL) was added, and the solution was stirred for 12 h. After removal of solvents under high vacuum, water was added, followed by extraction with CHCl₃. The organic extracts were washed with 1 N HCl and saturated NaHCO₃. Column chromatography (5% CH₃OH/CHCl₃) gave 1.05 g (91%) of 13.¹⁰

Desferrioxamine B hydrochloride (1) was generated according to our published report in 84% yield.¹⁰

N-(*tert*-Butoxycarbonyl)-*N*-(3,6,9-trioxadecyl)-*O*-benzylhydroxylamine (14). Sodium hydride (80% oil dispersion, 0.488 g, 16.3 mmol) was added to *N*-(*tert*-butoxycarbonyl)-*O*-benzylhydroxylamine¹¹ (2.66 g, 11.9 mmol) in dry DMF (20 mL), and stirring was continued for several minutes. 3,6,9-Trioxadecyl tosylate¹³ (4.93 g, 15.5 mmol) in DMF (3 mL) was added by syringe, and the suspension heated at 72 °C for 18 h under nitrogen. After cooling, the reaction was quenched with water (100 mL) and then extracted with ether (4 × 50 mL). The combined organic layers were washed with brine (100 mL), and solvent was removed in vacuo. Column chromatography with 4% EtOH/CHCl₃ produced 3.40 g (77%) of 14 as a liquid: NMR δ 1.50 (s, 9 H), 3.31 (s, 3 H), 3.5–3.7 (m, 12 H), 4.82 (s, 2 H), 7.25–7.41 (m, 5 H). Anal. (C₁₉H₃₁NO₆) C, H, N.

N-(3,6,9-Trioxadecyl)-*O*-benzylhydroxylamine (15). Compound 14 (3.37 g, 9.12 mmol) was treated with excess TFA in CH₂Cl₂ and worked up by the method of 9 to generate 2.24 g (91%) of 15 as a liquid: NMR δ 3.07 (t, 2 H, *J* = 5), 3.34 (s,

3 H), 3.43–3.67 (m, 10 H), 4.67 (s, 2 H), 7.2–7.4 (m, 5 H). Anal. (C₁₄H₂₃NO₄) C, H, N.

N-(Benzoyloxy)-*N*-(3,6,9-trioxadecyl)succinamic acid (16). A solution of 15 (2.20 g, 8.17 mmol) and succinic anhydride (1.29 g, 12.9 mmol) in pyridine (26 mL) was heated at 90 °C for 2 h under argon. After removal of the pyridine in vacuo, the residue was combined with ether (50 mL), followed by extraction with saturated aqueous NaHCO₃ (2 × 75 mL). The aqueous portion was extracted further with ether (2 × 50 mL), cooled to 0 °C, cautiously acidified with cold 6 N HCl (50 mL), and then extracted with CHCl₃ (4 × 75 mL). The CHCl₃ layer was washed with H₂O (50 mL), and solvent was removed by rotary evaporation. Column chromatography on silica gel (12% CH₃OH/CHCl₃) gave 2.79 g (92%) of 16 as an oil: NMR δ 2.52–2.73 (m, 4 H), 3.30 (s, 3 H), 3.4–3.8 (m, 12 H), 4.87 (s, 2 H), 6.53 (br s, 1 H), 7.33 (s, 5 H). Anal. (C₁₈H₂₇NO₇) C, H, N.

22-(*tert*-Butoxycarbonyl)-11,22-bis(benzoyloxy)-12,15-dioxo-11,16,22-triaza-2,5,8-trioxadocosane (17). Acid 16 (11.0 g, 29.8 mmol) and amine 7 (9.2 g, 29.9 mmol) were coupled by using diphenyl phosphorazidate and the method of 8 to give 18.6 g (94%) of 17 as an oil: NMR δ 1.28–1.70 (m + s, 15 H), 2.42 (t, 2 H, *J* = 7), 3.02–3.87 (m + s, 21 H), 4.78 (s, 2 H), 4.89 (s, 2 H), 6.0 (br s, 1 H), 7.25–7.44 (m, 10 H). Anal. (C₃₅H₅₃N₃O₉) C, H, N.

11,22-Bis(benzoyloxy)-12,15-dioxo-11,16,22-triaza-2,5,8-trioxadocosane (18). Excess TFA was added to 17 (16.0 g, 24.2 mmol) in CH₂Cl₂ at 0 °C, and the solution was stirred at room temperature and worked up by the method of 9 to give 12.0 g (87%) of 18 as an oil: NMR δ 1.24–1.62 (m, 6 H), 2.42 (t, 2 H, *J* = 7), 2.61–3.89 (m + s, 22 H), 4.66 (s, 2 H), 4.87 (s, 2 H), 6.0 (br s, 1 H), 7.2–7.4 (m, 10 H). Anal. (C₃₀H₄₆N₃O₇) C, H, N.

5,16-Bis(benzoyloxy)-4,12,15-trioxo-5,11,16-triaza-19,22,25-trioxahehexanoic acid (19). Compound 18 (3.40 g, 6.07 mmol) was reacted with succinic anhydride in pyridine following the procedure of 16 to produce 3.81 g (95%) of 19 as an oil: NMR δ 1.2–1.8 (m, 6 H), 2.38–2.91 (m, 8 H), 3.07–3.83 (m, 19 H), 4.79 (s, 2 H), 4.88 (s, 2 H), 5.7 (br s, 1 H), 6.62 (br s, 1 H), 7.33 (s, 10 H). Anal. (C₃₄H₄₉N₃O₁₀) C, H, N.

33-(*tert*-Butoxycarbonyl)-11,22,23-tris(benzoyloxy)-12,15,23,26-tetraoxo-11,16,22,27,33-pentaaza-2,5,8-trioxatriacantane (20). Acid 19 (3.78 g, 5.73 mmol) and amine 7 (2.03 g, 6.58 mmol) were coupled by using diphenyl phosphorazidate and the method of 8 to give 4.22 g (78%) of 20 as a waxy solid: NMR δ 1.2–1.7 (m + s, 21 H), 2.32–2.56 (m, 4 H), 2.67–2.93 (m, 4 H), 3.05–3.88 (m, 23 H), 4.78 (s, 2 H), 4.82 (s, 2 H), 4.88 (s, 2 H), 6.23 (br s, 2 H), 7.33 (s, 15 H). Anal. (C₅₁H₇₅N₅O₁₂) C, H, N.

11,22,33-Tris(benzoyloxy)-12,15,23,26-tetraoxo-11,16,22,27,33-pentaaza-2,5,8-trioxatriacantane (21). Excess TFA was added to 20 (2.05 g, 2.16 mmol) in CH₂Cl₂ at 0 °C. The solution was stirred at room temperature and worked up by the method of 9 to give 1.91 g (quantitative) of 21 as a waxy solid: NMR δ 1.18–1.70 (m, 12 H), 2.32–3.33 (m, 18 H), 3.39–3.80 (m, 14 H), 4.64 (s, 2 H), 4.80 (s, 2 H), 4.87 (s, 2 H), 6.23 (br s, 2 H), 7.2–7.4 (m, 15 H). Anal. (C₄₆H₆₇N₅O₁₀·H₂O) C, H, N.

11,22,33-Tris(benzoyloxy)-12,15,23,26,34-pentaoxo-11,16,22,27,33-pentaaza-2,5,8-trioxapentatriacontane (22). Compound 21 (1.1 g, 1.29 mmol) was treated with acetic anhydride in pyridine by the method of 13 to afford 1.05 g (91%) of 22 as a waxy white solid: NMR δ 1.13–1.77 (m, 12 H), 2.06 (s, 3 H), 2.3–2.9 (m, 8 H), 2.99–3.34 (m + s, 7 H), 3.48–3.77 (m, 16 H), 4.75 (s, 2 H), 4.80 (s, 2 H), 4.87 (s, 2 H), 6.2 (br s, 2 H), 7.33 (s, 15 H). Anal. (C₄₈H₆₉N₅O₁₁) C, H, N.

11,22,33-Tris(benzoyloxy)-12,15,23,26,34-pentaoxo-11,16,22,27,33-pentaaza-2,5,8,36,39,42-hexaoxatritetracontane (23). Compound 21 (3.91 g, 4.60 mmol) was reacted with 3,6,9-trioxadecanoyl chloride¹⁴ (NET₃/CH₂Cl₂) to give 4.0 g (78%) of 23: NMR δ 1.17–1.78 (m, 12 H), 2.3–2.9 (m, 8 H), 3.04–3.37 (m, 10 H), 3.4–3.8 (m, 24 H), 4.21 (s, 2 H), 4.76 (s, 2 H), 4.81 (s, 2 H), 4.88 (s, 2 H), 6.17–6.37 (m, 2 H), 7.34 (s, 15 H). Anal. (C₆₃H₇₉N₅O₁₄) C, H, N.

11,22,33-Trihydroxy-12,15,23,26,34-pentaoxo-11,16,22,27,33-pentaaza-2,5,8-trioxapentatriacontane (2). Compound 22 (2.6 g, 2.92 mmol) was dissolved in distilled CH₃OH (200 mL) in acid washed glassware, and 10% Pd-C (1.1 g) was introduced. The mixture was stirred under a hydrogen atmo-

(17) Bergeron, R. J.; McManis, J. S. The total synthesis desferrioxamines E and G. *Tetrahedron* 1990, 46, 5881–5888.

sphere for 2 h, solids were filtered using analytical grade Celite, and the filtrate was concentrated to furnish 1.56 g (86%) of 2 as an amorphous white solid: NMR (D₂O) δ 1.17-1.80 (m, 12 H), 2.11 (s, 3 H), 2.33-2.93 (m, 8 H), 3.15 (t, 4 H, $J = 7$), 3.33 (s, 3 H), 3.46-3.84 (m, 16 H). Anal. (C₂₇H₅₁N₅O₁₁) C, H, N.

11,22,33-Trihydroxy-12,15,23,26,34-pentaoxo-11,16,22,27,33-pentaaza-2,5,8,36,39,42-hexaoxatritetracontane (3). Compound 23 (2.0 g, 1.8 mmol) was debenzylated by the method of 2 to furnish 1.35 g (80%) of 3 as an amorphous solid. A sample of 3 (0.845 g) was passed through Sephadex LH-20 eluting with EtOH to afford an analytical sample (0.766 g) of 3: NMR (D₂O) δ 1.10-1.78 (m, 12 H), 2.33-2.93 (m, 8 H), 3.15 (t,

4 H, $J = 7$), 3.33 (s, 6 H), 3.47-3.85 (m, 24 H), 4.38 (s, 2 H). Anal. (C₃₂H₆₁N₅O₁₄) C, H, N.

Acknowledgment. Support was provided by National Institutes of Health Grant No. HL-42817.

Registry No. 2, 135638-91-4; 3, 135638-92-5; 7, 129245-21-2; 14, 135638-82-3; 15, 135638-83-4; 16, 135638-84-5; 17, 135638-85-6; 18, 135638-86-7; 19, 135638-87-8; 20, 135638-88-9; 21, 135638-89-0; 22, 135638-90-3; 23, 135658-21-8; PhCH₂ONHBOC, 79722-21-7; succinic anhydride, 108-30-5; 3,6,9-trioxadecyl tosylate, 62921-74-8; 3,6,9-trioxadecanoyl chloride, 63881-16-3; iron, 7439-89-6.

Synthesis and Anti-HIV-1 Activity of

4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one (TIBO) Derivatives. 2

Michael J. Kukla,*† Henry J. Breslin,† Craig J. Diamond,† Philip P. Grous,† Chih Y. Ho,† Milton Miranda,† James D. Rodgers,† Ronald G. Sherrill,† Erik De Clercq,§ Rudi Pauwels,§ Koen Andries,† Luc J. Moens,† Marcel A. C. Janssen,† and Paul A. J. Janssen†

Janssen Research Foundation, Spring House, Pennsylvania 19477, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium, and Janssen Research Foundation, Turnhoutseweg 30, B-2340 Beerse, Belgium. Received April 1, 1991

In the first paper of this series a new structure with anti-HIV-1 activity was disclosed and analogues were synthesized to explore the structure-activity relationship of changes in the substituent (R) attached at the N-6 position of 9. This study describes the syntheses and anti-HIV-1 testing of analogues with variations of the five-membered urea ring of the 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one (TIBO) structures. Although many different rings were synthesized to replace the cyclic urea of TIBO, most were found to be inactive in inhibiting the replication of the HIV-1 virus in MT-4 cells. The exceptions were replacement of the urea oxygen with sulfur or selenium to give the corresponding thio- or selenoureas. These were found to be more active than the oxygen counterparts. A small series of analogues was synthesized and tested which allowed direct comparison of urea and thiourea derivatives. Without exception, the latter were always more active than the former. The most active compound of this series (8d) was found to inhibit the HIV-1 virus with an IC₅₀ of 0.012 μ M which is comparable to that of AZT.

Introduction

In previous publications^{1,2} we described the discovery of a new series of compounds, 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one derivatives, that were assigned the acronym TIBO derivatives. The initial lead compounds, represented by structure 9, were found to specifically inhibit replication of HIV-1 virus, the causative agent for AIDS (acquired immune deficiency syndrome). The first paper in this series² described variation of the N-6 substituent and the resultant structure-activity relationships (SAR). Although those compounds had specific and consistent activity against HIV-1 virus, there was a need to find compounds with a higher level of potency. The best compound from the previous paper had activity comparable to DDI (2',3'-dideoxyinosine), which is currently undergoing clinical evaluation, but AZT (Zidovudine), the only approved drug against AIDS, was >2600 times as effective as our best analogue in blocking replication of the HIV-1 virus in the cellular assay used to determine relative potency. This publication describes efforts to systematically alter the 5-ring urea portion of the tricyclic TIBO structure 9 to determine the effects these changes might have on the relative potency of the resultant analogues to block HIV-1 replication.

Chemistry

In addition to the synthetic methods previously described² to obtain the basic ring system of the TIBO series, Scheme I illustrates an efficient and versatile synthesis of several analogues and intermediates. Chloroisatoic anhydride (1) is treated with alanine methyl ester hydrochloride in pyridine under reflux.³ Although the *l* isomer is pictured, the scheme has been carried out with both the *d* isomer and racemic material as well. The aromatic chloro substituent in 2 acts as a convenient block to para nitration in the next step, yet can be readily removed (step 8) if desired. Treatment of 2 with cold fuming nitric acid gave a 92% yield of 3. Reduction of 3 with lithium aluminum hydride (LAH) in refluxing glyme served to reduce both the carbonyls and the nitro functionalities to yield triamine 4. This material was specifically monoalkylated

- (1) Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.; Breslin, H.; Raeymaekers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. Potent and selective inhibition of HIV-1 replication *in vitro* by a novel series of TIBO derivatives. *Nature* 1990, 343, 470-474.
- (2) Kukla, M.; Breslin, H.; Pauwels, R.; Fedde, C.; Miranda, M.; Scott, M.; Sherrill, R.; Raeymaekers, A.; Van Gelder, J.; Andries, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one (TIBO) Derivatives. *J. Med. Chem.* 1991, 34, 746-751.
- (3) Kim, D. Improved Synthesis of 1,4-Benzodiazepine-2,5-diones. *J. Heterocycl. Chem.* 1975, 12, 1323.

* Janssen Research Foundation, Pennsylvania.

† Katholieke Universiteit Leuven.

‡ Janssen Research Foundation, Belgium.